Inflammation Affects Liver Function and the Metabolism of Voriconazole to Voriconazole-N-Oxide in Adult and Elderly Patients

Zaiming Liang, Mingjie Yu, Zhirui Liu, Fang Liu, Changsheng Jia, Lirong Xiong, Qing Dai, Shiwei Qin, Lin Cheng* and Fengjun Sun*

Department of Pharmacy, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China

Background: The inner association of inflammation with voriconazole (VCZ) metabolism has not been fully investigated. We intend to investigate the effects of inflammation on liver function, VCZ trough concentration (C₀), C₀/dose ratio and the ratio of VCZ to VCZ-N-oxide concentration (C₀/Cₙ) in adult and elderly patients.

Methods: A single-center retrospective study was conducted among patients who were treated in our hospital between January 2018 and December 2021. For each eligible patient, demographic details, medical history, laboratory parameters, procalcitonin (PCT), C reactive protein (CRP), and interleukin-6 (IL-6) were collected from the medical chart. VCZ Cₙ, TNF-α, IL-1β, IL-8, and IL-10 concentrations were detected in blood samples.

Results: A total of 356 patients were included in our study, with 195 patients in the adult cohort (<60 years) and 161 patients in the elderly cohort (≥60 years). In adult patients, CRP and IL-8 levels showed moderate association with VCZ C₀/Cₙ ratio (CRP: r = 0.512, p < 0.001; IL-8: r = 0.476, p = 0.002). IL-6 level showed a shallow association with VCZ C₀/Cₙ ratio both in adult and elderly patients (r = 0.355, p = 0.003; r = 0.386, p = 0.001). A significantly higher VCZ C₀, C₀/dose ratio and C₀/Cₙ ratio was observed in adult patients with severe inflammation compared with patients with moderate inflammation and no to mild inflammation, as reflected by PCT levels (p < 0.05). However, there was no significant difference observed among different inflammation degrees in elderly patients. Lower albumin (AL) and higher total bilirubin (TBIL) were observed along with the degree of inflammation in both adult and elderly patients, as reflected by CRP and PCT levels (p < 0.05).

Conclusion: Inflammation may affect the metabolism of VCZ to VCZ-N-oxide both in adult and elderly patients, and decreased plasma AL levels and increased TBIL levels under inflammatory conditions may also alter VCZ metabolism.

Keywords: voriconazole, inflammation, voriconazole-N-oxide, invasive fungal infections, plasma concentration, therapeutic drug monitoring
INTRODUCTION

Invasive fungal infections are common complications in immunosuppressed patients with high morbidity and mortality, such as patients with hematologic malignancy, solid organ transplant patients, and intensive care unit patients (Jenks et al., 2020). The incidence of invasive fungal infections in elderly patients is also obvious due to their decreased physiological defense function and immune function and complicated chronic diseases such as hypertension, diabetes, coronary atherosclerotic heart disease, etc. Voriconazole (VCZ) is a triazole antifungal agent widely used in patients with invasive Aspergillus or Candida infection (Patterson et al., 2016). It can be used as prophylactic or therapeutic. However, the therapy range of VCZ is narrow; in Europe, it is 1.0–5.5 μg/ml, and in China, it is 0.5–5.0 μg/ml (Chen et al., 2018; Ullmann et al., 2018). The metabolism of VCZ exhibits nonlinear pharmacokinetic characteristics with highly individual variability (Theuretzbacher et al., 2006). Many factors have been reported to contribute to the concentration variability of VCZ, including age, sex, drug-drug interactions, liver dysfunction, serum total bilirubin (TBIL), albumin (AL), cytochrome P450 (CYP) 2C19 gene polymorphism, and inflammation (Theuretzbacher et al., 2006; Bruggemann et al., 2009; Weiss et al., 2009; Veringa et al., 2017; Vreugdenhil et al., 2018; Xu et al., 2018; Shang et al., 2020).

Recently, much work has been done to explore the association of inflammation, as reflected by C reactive protein (CRP), interleukin-6 (IL-6), and IL-8, with VCZ concentration in transplantation patients, patients with blood diseases, and critically ill patients (van Wanrooy et al., 2014; Vreugdenhil et al., 2018; Gautier-Veyret et al., 2019). In our previous study, we identified that procalcitonin (PCT) is an independent factor affecting the VCZ trough concentration (C0) in elderly patients (Cheng et al., 2019). In the case of infection, immune cells release tumor necrosis factor (TNF-α), IL-1, IL-6, IL-8 and other signaling molecules, causing a systemic inflammatory response and stimulating different tissues (kidney, adipose tissue, lung, and liver) to secrete PCT, and their blood concentrations increase (Maruna et al., 2000). Although CRP, IL-6, and IL-8 were associated with VCZ C0 (Vreugdenhil et al., 2018) and CRP was correlated with the metabolism of VCZ in hematological patients (major adults) (Veringa et al., 2017), the effect of IL-6 and IL-8 on VCZ metabolism in adult and elderly patients is still unknown.

The VCZ C0 in the elderly cohort were significantly higher than those in the adult cohort at the same normal dosage, and the proportion of VCZ C0 > 5.0 μg/ml was 2.3 fold in the elderly cohort than that in the adult cohort (35.3% vs. 15.4%) (Cheng et al., 2019). In the previous study, we also found that for patients with CYP2C19 normal metaboliser, the VCZ C0, C0/dose ratio and the ratio of VCZ to VCZ-N-oxide concentration (C0/C0) were significantly higher in the elderly cohort than those in the adult cohort (Shang et al., 2020). The adverse effects of VCZ were the main cause of drug discontinuation, and thus lead to high mortality, which was associated with its trough concentration (Chan et al., 2020; Tang et al., 2020). Infection, chronic inflammation induced by chronic disease condition, and inflammation induced by the treatment of immunosuppressants were commonly existed both in adult and elderly patients with invasive fungal infections. In addition, liver function has been generally accepted to affect the concentration of VCZ, and the liver function of elderly patients is impaired, with decreased expression of albumin (AL) and CYP enzymes and

**TABLE 1 | Baseline characteristics of patients in the two cohorts.**

| Variable                          | Adult cohort (n = 195) | Elderly cohort (n = 161) | p value |
|-----------------------------------|-----------------------|-------------------------|---------|
| Sex                               |                       |                         | 0.110   |
| Male [no. (%)]                    | 116 (59.5)            | 109 (67.7)              |         |
| Female [no. (%)]                  | 79 (40.5)             | 52 (32.3)               |         |
| Age (yr)                          | 42.4 ± 12.0           | 71.9 ± 8.4              | 0.000   |
| Weight (kg)                       | 60.35 ± 12.05         | 57.84 ± 11.91           | 1.661   |
| Underlying diseases               |                       |                         |         |
| Leukemia [no. (%)]                | 77 (39.5)             | 12 (7.4)                | 0.000   |
| Hypertension [no. (%)]            | 41 (21.0)             | 66 (40.4)               | 0.000   |
| Diabetes mellitus [no. (%)]       | 24 (12.3)             | 49 (30.4)               | 0.000   |
| Kidney disease [no. (%)]          | 60 (30.8)             | 48 (29.8)               | 0.767   |
| Renal transplant [no. (%)]        | 8 (4.1)               | 0                       | 0.025   |
| Liver cancer [no. (%)]            | 0                     | 4 (2.5)                 | 0.088   |
| Pneumonia [no. (%)]               | 98 (50.3)             | 95 (59.0)               | 0.099   |
| Coronary atherosclerotic heart disease [no. (%)] | 1 (0.5) | 96 (59.6) | 0.000 |
| Fungus category                   |                       |                         |         |
| Aspergillus [no. (%)]             | 22 (11.3)             | 20 (12.4)               | 0.740   |
| Saccharomyces [no. (%)]           | 16 (8.2)              | 33 (20.5)               | 0.001   |
| Monilia [no. (%)]                 | 31 (15.9)             | 31 (19.3)               | 0.406   |
| Others [no. (%)]                  | 40 (20.5)             | 34 (21.1)               | 0.997   |
| Negative [no. (%)]                | 89 (45.6)             | 43 (26.7)               | 0.000   |
| Route of administration           |                       |                         | 0.362   |
| Intravenous [no. (%)]             | 142 (72.8)            | 114 (70.8)              |         |
| Oral [no. (%)]                    | 15 (7.7)              | 8 (5.0)                 |         |
| Mixed [no. (%)]                   | 38 (19.5)             | 39 (24.2)               |         |
| Daily voriconazole dose (mg/kg)   | 7.34 ± 1.36           | 7.33 ± 1.52             | 0.944   |
increased bilirubin concentrations (Schmucker, 2005; Dong et al., 2010), which may also affect VCZ metabolism.

VCZ metabolism is mainly mediated by the drug-metabolizing enzymes CYP2C19 and CYP3A4 in the liver, and the main metabolite in plasma is VCZ-N-oxide (accounting for 72%), with almost no activity (Hyland et al., 2003). To confirm the effect of inflammation on VCZ metabolism, the ratio of VCZ C0/CN might provide more information. The association of VCZ C0/CN with inflammation was not fully investigated in elderly patients. Combined with the impaired liver function and chronic inflammation of elderly patients, we intend to investigate the influence of inflammation on liver function and VCZ metabolism in elderly patients, and take the results of adults as control, so as to provide evidence of the rational use of VCZ in the elderly.

**Materials and Methods**

**Patients and Study Design**

A single center retrospective study was conducted. The patients were treated at Southwest Hospital, Chongqing, China between January 2018 and December 2021. Patients who met the following inclusion criteria were included: 1) aged ≥18 years; 2) hospitalized patient who had at least one steady-state VCZ C0 and CRP, PCT, or IL-6 concentration and liver function measured on the same day; and 3) not concomitantly using a strong inhibitor or inducer of CYP isoenzymes.

**Data Collection**

For each eligible patient, the following data were collected from the medical chart: 1) demographic details, including age, sex, and body weight; 2) medical history, including underlying disease, type of invasive fungal infections, and VCZ treatment regimen; 3) laboratory parameters, such as the liver function indices, ALT, AST, γ-GT, TBIL, and AL; and 4) inflammation markers, including PCT, CRP, and IL-6, which were measured routinely.

**VCZ C0 and VCZ CN Determination**

The VCZ C0 was defined as the concentration obtained after 3 days of VCZ therapy with a loading dose of 6 mg/kg by intravenous administration, and maintenance dose of 4 mg/kg by intravenous administration, or sequentially taking VCZ orally (200 mg). The VCZ C0 and VCZ CN were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previously described (Shang et al., 2020).

**Cytokine Concentration Determination**

Only discarded blood samples for VCZ C0 determination between May 2021 and November 2021 were used. A total of 161 of the VCZ C0 values matched with samples that were available for cytokine determination. IL-1β, IL-10, and TNF-α enzyme-linked immune sorbent assay (ELISA) kits were purchased from Jianglai Biological (Shanghai, China). IL-8 ELISA kits were purchased from Elabscience Biotechnology Co., Ltd. Plasma concentrations of the cytokines were measured according to the manufacturer’s instructions.

**Statistical Analysis**

IBM SPSS 19.0 (IBM Corp., Armonk, NY, United States) was used to perform the analysis. Categorical data were compared with the chi-squared test or Fisher’s exact test. To explore the possible association of inflammation with VCZ C0 and liver function, VCZ C0, C0/dose ratio, C0/CN ratio, and liver function of patients with no to mild inflammation (CRP, ≤40 mg/L; PCT, ≤0.25 ng/ml), with moderate inflammation (CRP, 41–200 mg/L; PCT, 0.25–0.5 ng/ml), and with severe inflammation (CRP, >200 mg/L; PCT, >0.5 ng/ml) were compared using a Kruskal–Wallisone test (three groups) or a Mann–Whitney U test (two groups). Pearson’s correlation test was performed to assess the association of inflammation, reflected by the above inflammatory markers, with VCZ C0, C0/dose ratio, and C0/CN ratio.

**Table 2**

| Parameter   | n  | Adult cohort | Elderly cohort | p value |
|-------------|----|--------------|----------------|---------|
| VCZ C0 (μg/ml) | 298 | 2.90 (1.50, 4.90) | 3.60 (2.30, 5.65) | 0.002   |
| VCZ C0/dose ratio (g/ml) | 217 | 0.42 (0.22, 0.72) | 0.53 (0.30, 0.81) | 0.036   |
| VCZ C0/CN ratio | 154 | 1.42 (0.67, 3.63) | 2.05 (1.11, 3.20) | 0.029   |

**Inflammation marker**

| Parameter   | n  | Adult cohort | Elderly cohort | p value |
|-------------|----|--------------|----------------|---------|
| CRP (mg/L)  | 89  | 42.90 (8.96, 119.55) | 64.07 (14.50, 131.00) | 0.106   |
| PCT (ng/ml) | 172 | 0.29 (0.10, 0.84) | 0.30 (0.11, 0.91) | 0.395   |
| TNF-α (pg/ml) | 53  | 4.59 (3.29, 7.58) | 27.17 (4.68, 60.36) | 0.000   |
| IL-6 (ng/L) | 139 | 26.63 (7.47, 97.30) | 33.87 (16.08, 75.54) | 0.336   |
| IL-8 (pg/ml) | 73  | 17.69 (16.11, 42.80) | 16.97 (13.79, 37.08) | 0.279   |
| IL-10 (pg/ml) | 46  | 30.41 (19.05, 58.30) | 62.99 (20.48, 116.82) | 0.094   |
| IL-1β (pg/ml) | 38  | 4.85 (2.53, 8.25) | 6.88 (3.76, 16.33) | 0.122   |

**Liver function**

| Parameter   | n  | Adult cohort | Elderly cohort | p value |
|-------------|----|--------------|----------------|---------|
| ALT (μL)    | 193 | 96.0 (74.0, 151.0) | 114.0 (79.5, 176.0) | 0.056   |
| AST (μL)    | 193 | 18.8 (9.6, 37.5) | 22.4 (10.86, 41.4) | 0.221   |
| γ-GT (μL)   | 193 | 24.2 (16.1, 50.6) | 34.2 (22.9, 56.9) | 0.000   |
| ALP (μL)    | 193 | 73.1 (43.9, 143.9) | 86.0 (43.8, 174.35) | 0.105   |
| TBIL (μmol/L) | 193 | 13.9 (9.2, 24.5) | 13.3 (9.65, 25.9) | 0.777   |
| AL (μL)     | 193 | 32.1 (29.1, 35.5) | 32 (29.05, 36.55) | 0.711   |

Data are presented as median (interquartile range). VCZ, voriconazole; CRP, C-reactive protein; PCT, procalcitonin; TNF, tumor necrosis factor; IL, interleukin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyl transferase; ALP, alkaline phosphatase; TBIL, total bilirubin; AL, albumin.
RESULTS
Patient Characteristics
A total of 356 patients were included in our study, with 195 patients in the adult cohort (<60 years) and 161 patients in the elderly cohort (≥60 years). The baseline patient characteristics are depicted in Table 1. The main baseline diseases in the elderly cohort were hypertension, diabetes mellitus, and coronary atherosclerotic heart disease, while the main baseline diseases in the adult cohort were leukemia and kidney disease. The main infected fungi were Monilia, Saccharomyces, and Aspergillus.

VCZ $C_0$, $C_0$/Dose Ratio and $C_0$/CN Ratio
The VCZ $C_0$, $C_0$/dose ratio, and $C_0$/CN ratio in the elderly cohort were significantly higher than those in the adult cohort ($p < 0.05$, Table 2).
Determination of Levels of Cytokines, CRP, and PCT
An overview of all measured laboratory parameters can be found in Table 2. The plasma levels of TNF-α and γ-GT in the elderly cohort were significantly higher than those in the adult cohort ($p < 0.001$).

Correlations Between Inflammatory Markers and VCZ $C_0$
In adult patients, CRP and PCT levels showed poor association with VCZ $C_0$ as well as IL-6 and IL-8 level (Figure 1). In elderly patients, only CRP level showed shallow association with VCZ $C_0$ (CRP: $r = 0.370, p = 0.017, 41$ observations) (Figure 2).
As significantly ($p = 0.003$) higher VCZ $C_0$ was observed in patients with severe inflammation [6.10 (IQR, 5.14–7.30) mg/L; $n = 7$] than in patients with moderate inflammation [3.50 (1.91–5.61) mg/L; $n = 39$] and no to mild inflammation [2.30 (1.25–4.10) mg/L; $n = 43$], as reflected by the CRP level in adult patients; there was a tendency in elderly patients ($p = 0.06$). These differences were shown in Figure 3.

A significantly ($p < 0.001$) higher VCZ $C_0$ was also observed in patients with severe inflammation [4.60 (IQR, 2.90–6.10) mg/L; $n = 66$] than in patients with moderate inflammation [2.70 (1.40–4.30) mg/L; $n = 28$] and no to mild inflammation [2.49 (1.40–4.30) mg/L; $n = 80$], as reflected by the PCT level in adult patients; there was a tendency in elderly patients ($p = 0.068$). These differences were shown in Figure 4.

**Correlations Between Inflammatory Markers and VCZ $C_0$/Dose Ratio**

In adult patients, CRP and IL-6 levels showed shallow association with VCZ $C_0$/dose ratio (CRP: $r = 0.326$, $p = 0.010$, 61 observations; IL-6: $r = 0.271$, $p = 0.048$, 61 observations). In elderly patients, CRP and IL-6 levels showed a stronger association with VCZ $C_0$/dose ratio (CRP: $r = 0.457$, $p < 0.001$, 61 observations; IL-6: $r = 0.359$, $p = 0.001$, 61 observations).

---

**FIGURE 3** | Association of CRP plasma levels with VCZ $C_0$, $C_0$/dose ratio and VCZ $C_0$/CN ratio in adult and elderly patients. (A,B) Distribution of VCZ $C_0$. (C,D) Distribution of VCZ $C_0$/dose ratio. (E,F) Distribution of VCZ $C_0$/CN ratio. **$p < 0.01$.**
There was no association between inflammatory biomarkers and VCZ C₀/dose ratio in elderly patients. As significantly (p = 0.010) higher VCZ C₀/dose ratio was observed in patients with severe inflammation [0.76 (0.69–0.93) g/ml; n = 7] than in patients with moderate inflammation [0.47 (0.29–0.76) g/ml; n = 25] and no to mild inflammation [0.31 (IQR, 0.17–0.53) g/ml; n = 29], as reflected by the CRP level in adult patients. There was no significant difference observed among different inflammation degrees in elderly patients (Figure 3).

A significantly (p = 0.001) higher VCZ C₀/dose ratio was also observed in patients with severe inflammation [0.63 (IQR, 0.39–0.97) g/ml; n = 46] than in patients with moderate inflammation [0.47 (0.25–0.71) g/ml; n = 23] and no to mild inflammation [0.35 (0.19–0.58) g/ml; n = 62], as reflected by the PCT level in adult patients. There was no significant difference observed among different inflammation degrees in elderly patients (Figure 4).

**Correlations Between Inflammatory Markers and VCZ C₀/C₉ Ratio**

In adult patients, CRP and IL-8 levels showed moderate association with VCZ C₀/C₉ ratio (CRP: r = 0.512, p < 0.001, 45 observations; IL-
TABLE 3 | Comparisons of liver function under different inflammation degrees as reflected by CRP levels in the two cohorts.

| Cohort       | Liver function | CRP (mg/ml) | p value |
|--------------|----------------|-------------|---------|
|              |                | 0–40        | 40–200  | 200– |
| Adult cohort | ALP (U/L)      | 93.0 (78.3, 128.0) | 99.5 (74.3, 153.8) | 79.5 (61.0, 87.8) | 0.173 |
|              | ALT (U/L)      | 19.9 (15.5, 42.1) | 18.7 (8.2, 43.9) | 11.0 (8.4, 13.6) | 0.157 |
|              | AST (U/L)      | 22.4 (19.8, 43.2) | 22.3 (16.7, 51.8) | 16.7 (13.4, 21.3) | 0.112 |
|              | γ-GT (U/L)     | 79.3 (65.1, 183.9) | 69.2 (35.0, 112.5) | 41.6 (28.3, 76.5) | 0.255 |
|              | TBIL (μmol/L)  | 12.0 (9.3, 19.2) | 15.5 (9.0, 22.3) | 22.6 (13.1, 30.0) | 0.441 |
|              | AL (g/L)       | 34.8 (30.4, 37.5) | 31.7 (29.5, 33.1) | 30.4 (27.1, 34.7) | 0.034 |
| Elderly cohort | ALP (U/L)      | 80.0 (67.0, 110.0) | 97.0 (71.0, 125.0) | — | 0.302 |
|              | ALT (U/L)      | 15.9 (12.6, 38.2) | 28.0 (14.4, 48.6) | — | 0.591 |
|              | AST (U/L)      | 25.8 (23.7, 57.9) | 34.2 (20.9, 68.2) | — | 0.983 |
|              | γ-GT (U/L)     | 82.0 (51.6, 153.4) | 50.0 (42.9, 114.1) | — | 0.561 |
|              | TBIL (μmol/L)  | 9.9 (9.1, 13.9) | 13.1 (10.6, 18.8) | — | 0.149 |
|              | AL (g/L)       | 32.7 (20.8, 33.6) | 28.0 (20.5, 32.1) | — | 0.017 |

*–*, not available; data are presented as median (interquartile range). ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyl transferase; TBIL, total bilirubin; AL, albumin.

8: r = 0.476, p = 0.002, 40 observations). PCT and IL-6 had shallow association with VCZ C0/CN ratio (PCT: r = 0.329, p = 0.004, 75 observations; IL-6: r = 0.355, p = 0.003, 67 observations) (Figure 1). In elderly patients, only IL-6 had shallow association with VCZ C0/CN ratio (IL-6: r = 0.386, p = 0.001, 67 observations) (Figure 2).

In adult patients, a significantly (p = 0.025) higher VCZ C0/CN ratio was observed in patients with severe inflammation [4.00 (IQR, 2.80–6.90) mg/L; n = 25] than in patients with moderate inflammation [3.22 (1.29–4.70) mg/L; n = 10] and no to mild inflammation [3.27 (2.30–5.34) mg/L; n = 39], as reflected by the PCT level; however, a tendency of significant association was observed, as reflected by the CRP level (p = 0.074). These differences were shown in Figure 4. In elderly patients, there was no significant difference in C0/CN ratio under different inflammation degrees, as reflected by CRP or PCT levels.

Liver Function Results
A significantly lower AL was observed in patients with severe inflammation than in patients with moderate inflammation and no to mild inflammation among adult patients, both reflected by CRP and PCT levels (p < 0.05), and the association was obvious in elderly patients, as reflected by CRP levels (p = 0.001) (Tables 3, 4; Figure 5). A significantly higher TBIL was observed in patients with severe inflammation than in patients with moderate inflammation and no to mild inflammation in both adult and elderly cohorts, as reflected by the PCT level (p < 0.01) (Table 4; Figure 6).

DISCUSSION
In the present study, we examined common inflammation markers, such as CRP, PCT, and IL-6, which were detected in the clinic, and four other cytokines, both pro- and anti-inflammatory, for their correlation with VCZ C0, C0/dose ratio and VCZ C0/CN ratio. CRP has been mostly investigated to be associated with VCZ C0 in hematologic malignancy and solid organ transplant patients (42–62 years) (van Wanrooy et al., 2014; Encalada Ventura et al., 2020).
In a prospective single-centre analysis performed in adult haematology patients receiving VCZ, which included 22 patients and 143 samples, the CRP, IL-6, and IL-8 levels were significantly associated with the VCZ C0 (CRP: r = 0.53, p < 0.0001; IL-6: r = 0.53, p < 0.0001; IL-8: r = 0.42, p < 0.0001) (Vreugdenhil et al., 2018). In a retrospective chart review of VCZ, a total of 77 samples from 63 patients were obtained, and the CRP level was significantly associated with the VCZ C0/dose ratio (r² = 0.26, p < 0.001) (Dote et al., 2016). In our study, 195 patients with 298 samples in the adult cohort and 161 patients with 255 samples in the elderly cohort were included, the correlation coefficient of CRP with VCZ C0 was 0.289 and 0.370 in adult and elderly patients, respectively. The low correlation coefficient may be due to 1-2 samples from one patient in our study, while 6-7 samples from one patient in the prospective study. The retrospective nature of the study and the large number of patients may contribute to the increased sample distribution widths.

Niioka et al., 2017 investigated the relationship of the CYP2C19 phenotype with the VCZ C0/CN ratio and demographic and clinical characteristics of Japanese patients, and found that patients with intravenous administration, higher CRP on the same day of VCZ plasma concentration measurement, CYP2C19 extensive metabolizer, and old age had higher VCZ C0/CN ratio. In our study, only 7.7% (adult) and 5.0% (elderly) patients had oral administration; the median CRP level was 42.90 in adult patients and 64.07 in elderly patients, respectively; the median value of C0/CN ratio was 1.42 in adult patients and 2.05 in elderly patients, and the VCZ C0/CN ratio in elderly patients was significantly higher than that in adult patients, which were consistent with previous study.

CRP concentrations was reported to significantly influence the VCZ C0/CN ratio even when corrected for other factors that could influence VCZ metabolism in a prospective observational study (Veringa et al., 2017). In addition to CRP level being significantly

![Figure 5](https://example.com/figure5.png)
associated with VCZ C₀/C₅ ratio in adult patients, our results also showed that IL-8 plasma levels were moderately associated with VCZ C₀/C₅ ratio in adult patients, and IL-6 plasma levels were shallowly associated with VCZ C₀/C₅ ratio in adult and elderly patients, which has not been reported previously. In an inflammatory state, LPS, TNF-α, IL-1β, and IL-6 can bind to cytokine receptors and TLR4 receptors on the cell membrane, regulating the expression of transporters and drug-related metabolic enzymes by targeting nuclear receptors, liver X receptor (LXR), pregnane X receptor (PXR) and constitutive rostan receptor (CAR), through the NF-κB signaling pathway (Wu and Lin, 2019). Furthermore, IL-6 can directly target liver cells and down regulate CYP2C19 and CYP3A4 gene expression during inflammation (Li et al., 2014; Klein et al., 2015). In particular, IL-6 caused a 30%–50% reduction in CYP2C19 mRNA expression in human hepatocytes (Aitken and Morgan, 2007; Rieger et al., 2015). The mechanism by which IL-8 influences the metabolism of VCZ is not clear. In the early stage of liver injury, IL-8 recruits neutrophils to the injured tissue through its specific receptors CXCR1 and CXCR2 and adheres to liver cells through intracellular adhesion factor 1, releasing myeloperoxidase and reactive oxygen species (ROS), resulting in hepatocyte damage (Heymann and Tacke, 2016; Khanam et al., 2017; Li et al., 2017). This may explain the positive correlation between the IL-8 level and VCZ C₀/C₅ ratio.

CRP, PCT, and IL-6 were routine inflammatory biomarkers detected in clinic. In the current study, we found that CRP and IL-8 levels were associated with VCZ C₀/C₅ ratio in adult patients, while only IL-6 level was shallowly associated with VCZ C₀/C₅ ratio in elderly patients, which indicated that IL-6 would be a better marker when evaluating the metabolism of VCZ in the elderly.

VCZ is bound to AL. Decreased AL will increase unbound fraction of VCZ. A positive relationship between VCZ plasma protein binding (PPB) and plasma AL concentrations was observed, indicating higher unbound VCZ concentrations with decreasing AL concentrations (Vanstraelen et al., 2014). Decreased AL levels were also associated with a significantly increased VCZ C₀/dose ratio (Dote et al., 2016). In patients with invasive aspergillosis, serum AL and γ-GT levels were significantly correlated with the VCZ clearance rate (Chantharit et al., 2020). Association of decreased AL and increased VCZ C₀ is related to reflection of impaired liver function (changes in intrinsic clearance). In our previous study, we determined that decreased AL was significantly associated with increased VCZ C₀ in adult patients (Cheng et al., 2019). In the present study, we found that, in both adult and elderly patients, a significantly lower AL was observed in patients with severe inflammation than in patients with moderate inflammation and no to mild inflammation, as reflected by CRP levels, which indicated that inflammation induced AL decreasing also contributed to VCZ metabolism.

Apart from the plasma AL concentration, the TBIL plasma concentration also significantly influences VCZ PPB (Vanstraelen et al., 2014). The presence of a bilirubin value of >1.5 mg/dL was associated with supratherapeutic concentrations in critically ill patients (Ruiz et al., 2019). In invasive fungal infection patients with liver dysfunction, VCZ clearance was significantly associated with TBIL and platelet count (Tang et al., 2020). Our previous study also determined that

![FIGURE 6](https://example.com/figure6.png)

**FIGURE 6 |** Association between PCT plasma levels and total bilirubin (TBIL) in adult and elderly patients. (A) Distribution of TBIL in adult patients. (B) Distribution of TBIL in elderly patients. **p < 0.01.
increased TBIL was significantly associated with increased VCZ C0 in adult patients (Cheng et al., 2019). The results of the current study showed that, in both adult and elderly patients, significantly increased TBIL was observed in patients along with the severity of inflammation, as reflected by PCT levels. The decreased AL level and increased TBIL level along with the degree of inflammation provided another explanation for the increased VCZ C0 under the inflammatory state.

This study has several limitations. We do not determine VCZ C0N in feces and urine specimens. A ratio of <2% VCZ is excreted through renal as the parent drug (Roffey et al., 2003; Geist et al., 2013; Hohmann et al., 2017). Geist et al. found that VCZ N-oxide and its conjugates excreted in urine within 12 h post dose during steady-state only accounted for 1% of the dose (Geist et al., 2013). In the current study, we also determine the C0 and C0N of VCZ at 12 h post drug administration during steady-state, and we propose that the C0N in feces and urine specimens may be rare. We previously demonstrated that VCZ C0 and C0N/C0 ratio were influenced by CYP2C19 polymorphisms in adult patients, but the influence was not obvious in elderly patients (Shang et al., 2020). However, the adult cohort was not stratified by CYP2C19 polymorphism status in the current analysis for its retrospective nature. Some other liver biomarkers such as ALP, ALT, AST, and γ-GT have been investigated to be associated with VCZ C0N, changes of these biomarkers reflect the function of liver, thus affecting VCZ metabolism. In the current study, we focus on the effect of inflammation on liver function and VCZ metabolism, and find that ALP, ALT, AST, and γ-GT are not significantly influenced by inflammation.

In conclusion, this study clearly demonstrates that inflammation, reflected by IL-6 and IL-8, may affect the metabolism of VCZ to VCZ-N-oxide in both adult and elderly patients. Furthermore, the decreased plasma AL levels and increased plasma TBIL levels under inflammatory conditions may also alter VCZ metabolism. The inflammation state and impaired liver function should be considered when optimizing VCZ doses to decrease the risk of adverse effects in elderly.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethics Committee of the First Affiliated Hospital of Army Medical University. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

LC and FS designed the study, performed the data analysis, and drafted the manuscript; ZL searched the data and did the detection; MY, ZL, QD and SQ did the detection; FL, CJ and LX searched the data. All authors approved the final version of the manuscript.

**FUNDING**

This work was supported by the Fund for the Medical Research Project of Science and Health of Chongqing, China (2021MSXM218).

---

**REFERENCES**

Aitken, A. E., and Morgan, E. T. (2007). Gene-specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes. *Drug Metab. Dispos* **35**(9), 1687–1693. doi:10.1124/dmd.107.015511

Brüggemann, R. J., Alfenaar, J. W., Blijlevens, N. M., Billaud, E. M., Kosterink, J. G., Verweij, P. E., et al. (2009). Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. *Clin. Infect. Dis.* 48(10), 1441–1458. doi:10.1086/598527

Chan, S. Y., Hughes, R. M., Woo, K., Perales, M. A., Neofytos, D., and Papanicolaou, G. (2020). Reasons for Voriconazole Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients: A Real-Life Paradigm. *Med. Mycol.* 58(8), 1029–1036. doi:10.1093/myco/myaa008

Chantharit, P., Tantasawat, M., Kasai, H., and Tanigawara, Y. (2020). Population Pharmacokinetics of Voriconazole in Patients with Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization. *Ther. Drug Monit.* 42(6), 872–879. doi:10.1097/FDT.0000000000001061

Chen, K., Zhang, X., Ke, X., Du, G., Yang, K., and Zhai, S. (2018). Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmaceutical Society. *Ther. Drug Monit.* 40(6), 663–674. doi:10.1097/FDT.0000000000001061

Cheng, L., Xiang, R., Liu, F., Li, Y., Chen, H., Yao, P., et al. (2019). Therapeutic Drug Monitoring and Safety of Voriconazole in Elderly Patients. *Int. Immunopharmacol.* 78, 100787. doi:10.1016/j.ijip.2019.100787

Dong, M. H., Bettencourt, R., Barrett-Connor, E., and Loomba, R. (2010). Alanine Aminotransferase Decreases with Age: the Rancho Bernardo Study. *PLoS One* **5**(12), e14254. doi:10.1371/journal.pone.0014254

Dote, S., Sawai, M., Nozaki, A., Naruhashi, K., Kobayashi, Y., and Nakashish, H. (2016). A Retrospective Analysis of Patient-specific Factors on Voriconazole Clearance. *J. Pharm. Health Care Sci.* 2, 10. doi:10.1186/s40780-016-0044-9

Encalada Ventura, M. A., van Wanrooy, M. J., Span, L. F., Rodgers, M. G., van den Hevel, R. U., Uges, D. R., et al. (2016). Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. *Antimicrob. Agents Chemother.* 60(5), 2727–2731. doi:10.1128/AAC.02830-15

Gautier-Veyret, E., Trufiot, A., Baily, S., Fonrose, X., Thiebaud-Bertrand, A., Tonini, J. et al. (2019). Inflammation Is a Potential Risk Factor of Voriconazole Overdose in Hematological Patients. *Fundam. Clin. Pharmacol.* 33(2), 232–238. doi:10.1111/fcp.12422

Geist, M. J., Egerer, G., Burhenne, J., Riedel, K. D., Weiss, J., and Mäkus, G. (2013). Steady-state Pharmacokinetics and Metabolism of Voriconazole in Patients. *J. Antimicrob. Chemother.* 68(11), 2592–2599. doi:10.1093/jac/dkt229

Heymann, F., and Tacke, F. (2016). Immunology in the Liver-Frrom Homeostasis to Disease. *Nat. Rev. Gastroenterol. Hepatol.* **13**(2), 88–110. doi:10.1038/nrgastro.2015.204

Hohmann, N., Kreuter, R., Blank, A., Weiss, J., Burhenne, J., Haefeli, W. E., et al. (2017). Autoinhibitory Properties of the Parent but Not the N-Oxide Metabolite...
Liang et al. Metabolism of Voriconazole to Voriconazole-N-Oxide

Contribute to Infusion Rate-dependent Voriconazole Pharmacokinetics. Br. J. Clin. Pharmacol. 83 (9), 1954–1965. doi:10.1111/bcp.13297

Hyland, R., Jones, B. C., and Smith, D. A. (2003). Identification of the Cytochrome P450 Enzymes Involved in the N-Oxidation of Voriconazole. Drug Metab. Dispos. 31 (5), 540–547. doi:10.1124/dmd.31.5.540

Jenkins, J. D., Cornely, O. A., Chen, S. C., Thompson, G. R., 3rd, and Hoenigl, M. (2020). Breakthrough Invasive Fungal Infections: Who Is at Risk? Mycoses 63 (10), 1021–1032. doi:10.1111/myc.13148

Khanam, A., Trehanpati, N., Rase, P., Rastogi, A., Guzman, C. A., and Sarin, S. K. (2017). Blockade of Neutrophil’s Chemokine Receptors CXCR1/2 Abrogate Liver Damage in Acute-On-Chronic Liver Failure. Front. Immunol. 8, 464. doi:10.3389/fimmu.2017.00464

Klein, M., Thomas, M., Hofmann, U., Seehofer, D., Damm, G., and Zanger, U. M. (2014). Evaluation of Primary Human Hepatocytes and HepaRG Cells. Drug Metab. Dispos. 42 (3), 273–283. doi:10.1124/dmd.114.060962

Li, A. P., Yang, Q., Vermet, H., Raoust, N., Kléber, S., and Fabre, G. (2014). Evaluation of Human Hepatocytes under Prolonged Culture in a Novel Medium for the Maintenance of Hepatic Differentiation: Results with the Model Pro-inflammatory Cytokine Interleukin 6. Drug Metab. Lett. 8 (1), 12–18. doi:10.2174/1872328080109029115351

Li, J. J., Ma, F. X., Wang, Y. W., Chen, F., Lu, S. H., Chi, Y., et al. (2017). Knockdown of IL-8-Involved Premature Senescence of Placenta-Derived Mesenchymal Stem Cells. Stem Cell Dev. 26 (12), 912–939. doi:10.1089/scd.2016.0324

Maruna, P., Nedělková, K., and Gürlich, R. (2000). Physiology and Genetics of Procainamide. Physiol. Res. 49 Suppl 1 (Suppl. 1), S57–S61.

Niitaka, T., Fujishima, N., Abumiya, M., Yamashita, T., Ubukawa, K., Nara, M., et al. (2017). Relationship between the CYP2C19 Phenotype Using the Voriconazole-To-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients with Different CYP2C19 Genotypes. Ther. Drug Monit. 39 (5), 514–521. doi:10.1093/tdm/flx044

Patterson, T. F., Thompson, G. R., 3rd, Denning, D. W., Fishman, J. A., Hadley, S., Herbrecth, R., et al. (2016). Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 63 (4), 433–442. doi:10.1093/cid/ciw326

Rieger, J. K., Reutter, S., Hofmann, U., Schwab, M., and Zanger, U. M. (2015). Inflammation-associated microRNA-130b Down-Regulates Cytochrome P450 Activities and Directly Targets CYP2C9. Drug Metab. Dispos. 43 (6), 884–888. doi:10.1124/dmd.114.062844

Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezquel, S. G., Nedderman, A. N., et al. (2003). The Disposition of Voriconazole in Mouse, Rat, Rabbit, guinea Pig, Dog, and Human. Drug Metab. Dispos. 31 (6), 731–741. doi:10.1124/dmd.31.6.731

Ruiz, J., Gordon, M., Villarreal, E., Perucchi, M., Marqués, R. M., Poveda-Andrés, J. L., et al. (2019). Impact of Voriconazole Plasma Concentrations on Treatment Response in Critically Ill Patients. J. Clin. Pharm. Ther. 44 (4), 572–578. doi:10.1111/jcpt.12817

Schmucker, D. L. (2005). Age-related Changes in Liver Structure and Function: Implications for Disease? Exp. Gerontol. 40 (8-9), 650–659. doi:10.1016/j.exger.2005.06.009

Shang, S., Cheng, L., Li, X., Xiang, R., Yu, M., Xiong, L., et al. (2020). Effect ofCYP2C19polymorphism on the Plasma Voriconazole Concentration and voriconazole-to-voriconazole-N-oxide Concentration Ratio in Elderly Patients. Mycoses 63, 1181–1190. doi:10.1111/myc.13105

Tang, D., Yan, M., Song, B. L., Zhao, Y. C., Xiao, Y. W., Wang, F., et al. (2020). Population Pharmacokinetics, Safety and Dosing Optimization of Voriconazole in Patients with Liver Dysfunction: A Prospective Observational Study. Br. J. Clin. Pharmacol. 87 (4), 1890–1902. doi:10.1111/bcp.14574

Theuretzbacher, U., Ille, F., and Derendorf, H. (2006). Pharmacokinetic/pharmacodynamic Profile of Voriconazole. Clin. Pharmacokinet. 45 (7), 649–663. doi:10.2165/00003088-200645070-00002

Ullman, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., et al. (2018). Diagnosis and Management of Aspergillus Diseases: Executive Summary of the 2017 ESCMID-ECMM-ERS Guideline. Clin. Microbiol. Infect. 24 (Suppl. 1), e1–e38. doi:10.1016/j.cmi.2018.01.002

van Wanrooy, M. J., Span, L. F., Rodgers, M. G., van den Heuvel, E. R., Uges, D. R., van der Werf, T. S., et al. (2014). Inflammation Is Associated with Voriconazole Trough Concentrations. Antimicrob. Agents Chemother. 58 (12), 7098–7101. doi:10.1128/AAC.03820-14

Vanstraelen, K., Wauters, J., Vercammen, L., De Loer, H., Maertens, J., Lagrou, K., et al. (2014). Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients. Antimicrob. Agents Chemother. 58 (11), 6782–6789. doi:10.1128/AAC.03641-14

Veringa, A., Ter Avest, M., Span, L. F., van den Heuvel, E. R., Towu, D. J., Zijlstra, J. G., et al. (2017). Voriconazole Metabolism Is Influenced by Severe Inflammation: a Prospective Study. J. Antimicrob. Chemother. 72 (1), 261–267. doi:10.1093/jac/dkw439

Vreugdenhil, R., van der Velden, W. J. F. M., Feuth, T., Kos, M., Pickkers, P., van de Veerdonk, F. L., et al. (2018). Moderate Correlation between Systemic IL-6 Responses and CRP with Trough Concentrations of Voriconazole. Br. J. Clin. Pharmacol. 84 (9), 1980–1988. doi:10.1111/bcp.13627

Weiss, I., Ten Hoevel, M. M., Burhenne, J., Walter-Sack, I., Hofmann, M. M., Rengelshausen, J., et al. (2009). CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole. J. Clin. Pharmacol. 49 (2), 196–204. doi:10.1177/0091270P08327537

Wu, K. C., and Lin, C. J. (2019). The Regulation of Drug-Metabolizing Enzymes and Membrane Transporters by Inflammation: Evidences in Inflammatory Diseases and Age-Related Disorders. J. Food Drug Anal. 27 (1), 48–59. doi:10.1016/j.jfda.2018.11.005

Xu, R. A., Gu, E. M., Liu, T. H., Ou-yang, Q. G., Hu, G. X., and Cai, J. P. (2018). The Effects of Cytochrome P450 2C19 Polymorphism on the Metabolism of Voriconazole In Vitro. Infect. Drug Resist. 11, 2129–2135. doi:10.2147/idr.s179078

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liang, Yu, Liu, Liu, Jia, Xiong, Dai, Qin, Cheng and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.